Form 8-K - Current report:
SEC Accession No. 0001140361-24-030348
Filing Date
2024-06-17
Accepted
2024-06-17 16:30:28
Documents
14
Period of Report
2024-06-12
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20031213_8k.htm   iXBRL 8-K 49641
2 EXHIBIT 3.1 ef20031213_ex3-1.htm EX-3.1 8400
  Complete submission text file 0001140361-24-030348.txt   201789

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20240612.xsd EX-101.SCH 3907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20240612_lab.xml EX-101.LAB 22691
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20240612_pre.xml EX-101.PRE 16580
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20031213_8k_htm.xml XML 4201
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 241048702
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)